Advanced funding secured ahead of R&D rebate
Filed with ASX · · 2 pages · English
Earlier from Noxopharm
- Significant results from new brain cancer drugs
- Noxopharm Targets Clinical Trial for First-in-Class Drug
- Significant CRO-67 Results in Pancreatic Cancer Studies
- June 2024 Quarterly Activities Report and Appendix 4C
- March 2024 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- New funding from sophisticated investors
- September 2024 Quarterly Activities report and Appendix 4C
- Additional convertible note for long-term shareholder
- December 2024 Quarterly Activities Report and Appendix 4C
- SOF-SKN passes required in vitro safety tests
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm